In:
Hypertension, Ovid Technologies (Wolters Kluwer Health), Vol. 46, No. 3 ( 2005-09), p. 622-627
Abstract:
The endothelial lectinlike, oxidatively (ox-) modified LDL receptor LOX-1 is a critical player in the pathogenesis of atherosclerosis and myocardial ischemia. Ox-LDL binding of LOX-1 results in the expression of various adhesion molecules, which attract monocytes to endothelial cells, an initial step in atherogenesis. We wished to examine the role of the ox-LDL/LOX-1 signaling pathway in fibroblasts, which naturally express low levels of LOX-1. Rat cardiac fibroblasts were transfected with either cytomegalovirus (CMV)-LOX-1 wt (amino acids [aa] 1 to 273) or CMV-LOX-1 1-261 (an ox-LDL–binding negative mutant, aa 1 to 261) plasmid. Western blots showed that LOX-1 protein expression was increased significantly in cells transfected with CMV-LOX-1 wt or CMV-LOX-1 1-261 plasmid ( P 〈 0.01 vs control). Fibroblasts transfected with CMV-LOX-1 wt showed ox-LDL binding, whereas fibroblasts without transfection and those transfected with CMV-LOX-1 1-261 did not bind ox-LDL. Compared with untransfected cells, ox-LDL treatment (50 μg/mL, 24 hours) markedly induced the expression of the leukocyte adhesion molecules intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM)-1 as well as matrix metalloproteinase (MMP)-1 in cells transfected with CMV-LOX-1 wt ( P 〈 0.05) but not in cells transfected with CMV-LOX-1 1-261 . Concurrently, ox-LDL treatment enhanced the phosphorylation of p38 mitogen-activated protein kinase (MAPK) ( P 〈 0.05 vs control) in CMV-LOX-1 wt –transfected cells. These data suggest that in cardiac fibroblasts, ox-LDL binds to LOX-1 and activates p38 MAPK, followed by the expression of ICAM-1, VCAM-1, and MMP-1. Thus, fibroblasts transform into an endothelial phenotype on transfection with CMV-LOX-1 wt and subsequent exposure to ox-LDL. This study provides a useful model system (plasmid-transfected fibroblasts) to study the molecular biology of LOX-1.
Type of Medium:
Online Resource
ISSN:
0194-911X
,
1524-4563
DOI:
10.1161/01.HYP.0000179045.95915.b0
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2005
detail.hit.zdb_id:
2094210-2
Permalink